Tritoqualine

Tritoqualine

SCHEMBL28974

CCOc1c(N)c2c(c(OCC)c1OCC)C(C1c3c(cc4c(c3OC)OCO4)CCN1C)OC2=O

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 4/20 0.68
TUBB P07437 4/20 0.68
TUBA3C P0DPH7 4/20 0.68
TUBA1B P68363 4/20 0.68
TUBA4A P68366 4/20 0.68
TUBB4B P68371 4/20 0.68
TUBB3 Q13509 4/20 0.68
TUBB2A Q13885 4/20 0.68
TUBB8 Q3ZCM7 4/20 0.68
TUBA3E Q6PEY2 4/20 0.68
TUBA1A Q71U36 4/20 0.68
TUBA1C Q9BQE3 4/20 0.68
TUBB6 Q9BUF5 4/20 0.68
TUBB2B Q9BVA1 4/20 0.68
TUBB1 Q9H4B7 4/20 0.68
CYP3A4 P08684 7/20 0.64
CYP2C9 P11712 4/20 0.64
CYP2C19 P33261 4/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tritoqualine SCHEMBL1627004 1.00 TUBB4A (0.68) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Tritoqualine SCHEMBL29606368 1.00 TUBB4A (0.68) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Tritoqualine SCHEMBL10076978 1.00 TUBB4A (0.68) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Tritoqualine SCHEMBL14135610 1.00 TUBB4A (0.68) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Tritoqualine SCHEMBL16876635 0.99 TUBB4A (0.67) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2631317 0.98 TUBB4A (0.68) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Tritoqualine SCHEMBL18037822 0.97 TUBB4A (0.64) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Tritoqualine SCHEMBL18037824 0.96 TUBB4A (0.64) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Tritoqualine SCHEMBL18037823 0.96 TUBB4A (0.64) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Tritoqualine SCHEMBL18037828 0.95 TUBB4A (0.63) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704971-A1 GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY Cognito Therapeutics, Inc. (US) 2026-03-11 EP claimed
WO-2024229174-A1 GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY Cognito Therapeutics, Inc. (US) 2024-11-07 WO claimed
EP-4138833-B1 USE OF TRITOQUALINE FOR TREATING DRY EYES, MEIBOMIAN GLAND DYSFUNCTIONS AND LACRIMAL GLAND DYSFUNCTIONS H4 ORPHAN PHARMA (FR) 2024-06-05 EP claimed
US-20230201190-A1 USE OF MULTIFUNCTIONAL LIGANDS FOR TREATING THE RESPIRATORY DISTRESS AND CYTOKINE STORM SYNDROMES ASSOCIATED WITH CORONAVIRUS VIRAL INFECTIONS TERRASSE, Gaëtan (FR) 2023-06-29 US claimed
CN-116322689-A Use of multifunctional ligands for the treatment of respiratory distress and cytokine storm syndrome associated with coronavirus viral infection H4奥芬制药 2023-06-23 CN claimed
US-20230181562-A1 USE OF A MULTIFUNCTIONAL LIGAND FOR TREATING DRY EYES, MEIBOMIAN GLAND DYSFUNCTIONS AND LACRIMAL GLAND DYSFUNCTIONS TERRASSE, Gaëtan (FR) 2023-06-15 US claimed
EP-4138833-A1 USE OF A MULTIFUNCTIONAL LIGAND FOR TREATING DRY EYES, MEIBOMIAN GLAND DYSFUNCTIONS AND LACRIMAL GLAND DYSFUNCTIONS H4 Orphan Pharma (FR) 2023-03-01 EP claimed
EP-2854947-B1 USE OF AN H4 AGONIST MOLECULE FOR TREATING CYSTIC FIBROSIS TERRASSE GAETAN (FR) 2021-12-29 EP claimed
WO-2021213891-A1 USE OF A MULTIFUNCTIONAL LIGAND FOR TREATING DRY EYES, MEIBOMIAN GLAND DYSFUNCTIONS AND LACRIMAL GLAND DYSFUNCTIONS H4 ORPHAN PHARMA (FR) 2021-10-28 WO claimed
EP-2459227-B1 Prodrugs containing an aromatic amine connected by an amide bond to a carrier ASCENDIS PHARMA AS (DK) 2021-03-17 EP claimed
US-6632217-B2 Implantable osmotic pump MICROSOLUTIONS, INC. 2003-10-14 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-20030135202-A1 Implantable osmotic pump MICROSOLUTIONS, INC. 2003-07-17 US claimed
US-20030104013-A1 Anti-allergic pharmaceutical composition containing at least one allergen and at least one antihistamine compound ANTIALIS (FR) 2003-06-05 US claimed
US-20020183722-A1 Implantable osmotic pump MICROSOLUTIONS, INC., 2002-12-05 US claimed
WO-2002085428-A2 IMPLANTABLE OSMOTIC PUMP MICROSOLUTIONS, INC. (US) 2002-10-31 WO claimed
WO-2002078736-A2 ANTIALLERGIC PHARMACEUTICAL COMPOSITION ANTIALIS (FR) 2002-10-10 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0201359-A2 Use of phthalide isoquinoline derivatives for treatments inhibiting the formation of lipid peroxides MITSUBISHI KASEI CORPORATION (JP) 1986-11-12 EP claimed